Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05099614

Naloxone Auto-injection in Healthy Volunteers

Naloxone Administration Via Auto-injection in Healthy Volunteers

Sponsor: U.S. National Science Foundation

Interventions Naloxone hydrochloride injection solution, SmartDose wearable auto injector and mobile respiratory sensing system

Updated 3 times since 2021 Last updated: Oct 28, 2021 Started: Mar 10, 2021 Primary completion: Apr 5, 2021 Completion: Apr 5, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A EARLY_PHASE1 clinical study on Overdose Antidote, this trial is completed. The trial is conducted by U.S. National Science Foundation and has accumulated 3 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Nov 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

U.S. National Science Foundation
University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seattle, United States